Étiquette : DMT

Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning, Briony J. Catlow et al., 2013

Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditionning CATLOW B.J., SONG S., PAREDES D.A., KIRSTEIN C.L., SANCHEZ-RAMOS J. Experimental Brain Research, 2013, 228, 481-491. Doi : 10.1007/s00221-013-3579-0   Abstract Drugs that modulate serotonin (5-HT) synaptic concentrations impact neurogenesis and hippocampal (HPC)-dependent learning. The primary objective is to determine the extent to which psilocybin (PSOP) modulates neurogenesis and thereby affects acquisition and extinction of HPC-dependent trace fear conditioning. PSOP, the 5-HT2A agonist 25I-NBMeO and the 5-HT2A/C antagonist ketanserin were administered via an acute intraperitoneal injection to mice. Trace fear conditioning was measured as the amount of time spent immobile in the presence of the conditioned [...]

Lire la suite

Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution, M. V. Uthaug et al., 2018

Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution M. V. Uthaug, K. van Oorsouw, K. P. C. Kuypers, M. van Boxtel, N. J. Broers, N. L. Mason, S. W. Toennes, J. Riba, J. G. Ramaekers Psychopharmacology, 2018 https://doi.org/10.1007/s00213-018-4988-3   Abstract Rationale : Ayahuasca is a psychotropic plant tea from South America used for religious purposes by indigenous people of the Amazon. Increasing evidence indicates that ayahuasca may have therapeutic potential in the treatment of mental health disorders and can enhance mindfulness-related capacities. Most research so far has focused on acute and sub-acute effects of ayahuasca on [...]

Lire la suite

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer, Charles S. Grob et al., 2010

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer Charles S. Grob,  Alicia L. Danforth,  Gurpreet S. Chopra,  Marycie Hagerty, Charles R. McKay, Adam L. Halberstadt,  George R. Greer Archive of  General Psychiatry, 2010, 68, (1), 71–78 doi: 10.1001/archgenpsychiatry.2010.116   Context : Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer. Objective : To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and [...]

Lire la suite

Ayahuasca Scientific Papers, AEDMP, 2013

Ayahuasca Scientific Papers AEDMP - Asociación para el Estudio y la Divulgación de la Medicina Psicodélica Research conducted by: Genís Oña -2013- Asociación para el Estudio y la Divulgación de la Medicina Psicodélica. Castellarnau, 11 2º 1ª 43004 Tarragona Spain Tel. 675 55 33 44 Email: medicina.psicodelica@hotmail.com www.medicinapsicodelica.org   Content _____________________________________ 1. What is ayahuasca? 2. Scientific papers about ayahuasca arranged chronologically (1969-2013) - G. R. Dolmatoff (1969). El contexto cultural de un alucinógeno aborigen : Banisteriopsis Caapi - C. Grob et al. (1996). Human Psychopharmacology of Hoasca, a Plant Hallucinogen Used in Ritual Context in Brazil - J. C. Callaway et al. (1999). Pharmacokinetics of Hoasca Alkaloids in Healthy Humans - B. Shanon (2000). Ayahuasca and [...]

Lire la suite

Chronic, Intermittent Microdoses of the Psychedelic N,N‑Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents, Lindsay P. Cameron et al., 2019

Chronic, Intermittent Microdoses of the Psychedelic N,N‑Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson ACS Chemical Neurosciences, 2019 DOI: 10.1021/acschemneuro.8b00692   ABSTRACT : Drugs capable of ameliorating symptoms of depression and anxiety while also improving cognitive function and sociability are highly desirable. Anecdotal reports have suggested that serotonergic psychedelics administered in low doses on a chronic, intermittent schedule, so-called “microdosing”, might produce beneficial effects on mood, anxiety, cognition, and social interaction. Here, we test this hypothesis by subjecting male and female Sprague Dawley rats to behavioral testing following the [...]

Lire la suite

Cultural Neurophenomenology of Psychedelic Thought : Guiding the “Unconstrained” Mind Through Ritual Context, Michael Lifshitz et al., 2018

Cultural Neurophenomenology of Psychedelic Thought : Guiding the “Unconstrained” Mind Through Ritual Context Michael Lifshitz, Eli Sheiner, and Laurence J. Kirmayer The Oxford Handbook of Spontaneous Thought : Mind-Wandering, Creativity, and Dreaming, Edited by Kalina Christoff and Kieran C.R. Fox May 2018 DOI: 10.1093/oxfordhb/9780190464745.013.4   Abstract This chapter explores psychedelics as catalysts of spontaneous thought. Classic serotonergic psychedelics such as psilocybin, LSD, and ayahuasca can induce potent alterations in cognition and perception. The chapter reviews research on these substances through the lens of cultural neurophenomenology, which aims to trace how neurobiology and sociocultural factors interact to shape experience. After a decades-long hiatus, the scientific study of psychedelics [...]

Lire la suite

Human hallucinogen research : Guidelines for safety, Matthew W. Johnson et al., 2008

Human hallucinogen research : Guidelines for safety. Matthew W. Johnson,  William A. Richards, Roland R. Griffiths Journal of Psychopharmacology, 2008, 22, 603–620. doi:10.1177/0269881108093587   Abstract There has recently been a renewal of human research with classical hallucinogens (psychedelics). This paper first briefly discusses the unique history of human hallucinogen research, and then reviews the risks of hallucinogen administration and safeguards for minimizing these risks. Although hallucinogens are relatively safe physiologically and are not considered drugs of dependence, their administration involves unique psychological risks. The most likely risk is overwhelming distress during drug action ('bad trip'), which could lead to potentially dangerous behaviour such as leaving the [...]

Lire la suite

Unifying Theories of Psychedelic Drug Effects, Link R. Swanson, 2018

Unifying Theories of Psychedelic Drug Effects Link R. Swanson Frontiers in Pharmacology, 2018, Volume 9, Article 172, 1-23 www.frontiersin.org (2 March 2018) doi: 10.3389/fphar.2018.00172   Abstract How do psychedelic drugs produce their characteristic range of acute effects in perception, emotion, cognition, and sense of self? How do these effects relate to the clinical efficacy of psychedelic-assisted therapies? Efforts to understand psychedelic phenomena date back more than a century in Western science. In this article I review theories of psychedelic drug effects and highlight key concepts which have endured over the last 125 years of psychedelic science. First, I describe the subjective phenomenology of acute psychedelic effects using [...]

Lire la suite

Potential Therapeutic Effects of Psilocybin, Matthew W. Johnson & Roland R. Griffiths, 2017

Potential Therapeutic Effects of Psilocybin Matthew W. Johnson & Roland R. Griffiths Neurotherapeutics, 2017, 14, 734–740 DOI 10.1007/s13311-017-0542-y Abstract Psilocybin and other 5-hydroxytryptamine2A agonist classic psychedelics have been used for centuries as sacraments within indigenous cultures. In the mid-twentieth century they were a focus within psychiatry as both probes of brain function and experimental therapeutics. By the late 1960s and early 1970s these scientific inquires fell out of favor because classic psychedelics were being used outside of medical research and in association with the emerging counter culture. However, in the twenty-first century, scientific interest in classic psychedelics has returned and grown as a result of [...]

Lire la suite

Psychedelic drug use in healthy individuals: a review of benefits, costs, and implications for drug policy, James W.B. Elsey, 2017

Psychedelic drug use in healthy individuals : a review of benefits, costs, and implications for drug policy, James W.B. Elsey Roeterseiland Campus, Building G, 129 Nieuwe Achtergracht, Amsterdam, Postbus 15933, Noord Holland, 1001 NK, the Netherlands. Drug Science, Policy and Law, 2017, 3, 1–11. doi: 10.1177/2050324517723232   Abstract The potential of psychedelic drugs in the treatment of mental health problems is increasingly being recognized. However, relatively little thrust has been given to the suggestion that individuals without any mental health problems may benefit from using psychedelic drugs, and that they may have a right to do so. This review considers contemporary research into the use of psychedelic [...]

Lire la suite